Chemotherapy-Induced Nausea and Vomiting (CINV) – Antiemetics 
Therapy Initiation Resources
- QOPI Measures
- SMT26 – Serotonin Antagonist prescribed or administered with moderate/high emetic risk chemotherapy
- SMT27 – Corticosteroids and Serotonin Antagonist prescribed or administered with moderate/high emetic risk chemotherapy
- SMT28 – NK1 Receptor Antagonist and Olanzapine prescribed or administered with high emetic risk chemotherapy
- SMT28a – NK1 Receptor Antagonist (aprepitant, fosaprepitant, netupitant) or Olanzapine administered for low or moderate emetic risk Cycle 1 chemotherapy (Lower Score – Better)
- SMT29 – Antiemetics prescribed or administered appropriately with moderate/high emetic risk chemotherapy
- SMT29a – Antiemetic therapy prescribed for highly emetogenic chemotherapy risk
- SMT29b – Antiemetic therapy administered for highly emetogenic chemotherapy risk
- SMT29c – Antiemetic therapy prescribed for moderately emetogenic chemotherapy risk
- SMT29d – Antiemetic therapy administered for moderately emetogenic chemotherapy risk